Jump Financial LLC Acquires 15,199 Shares of Enovis Co. (NYSE:ENOV)

Jump Financial LLC grew its stake in Enovis Co. (NYSE:ENOVFree Report) by 132.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 26,668 shares of the company’s stock after purchasing an additional 15,199 shares during the period. Jump Financial LLC’s holdings in Enovis were worth $1,494,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. Channing Capital Management LLC increased its holdings in shares of Enovis by 26.6% during the fourth quarter. Channing Capital Management LLC now owns 1,588,417 shares of the company’s stock worth $88,983,000 after buying an additional 334,154 shares in the last quarter. Invesco Ltd. increased its holdings in Enovis by 116.2% during the 3rd quarter. Invesco Ltd. now owns 472,713 shares of the company’s stock valued at $24,926,000 after purchasing an additional 254,097 shares in the last quarter. Diamond Hill Capital Management Inc. raised its position in Enovis by 9.9% in the 3rd quarter. Diamond Hill Capital Management Inc. now owns 2,429,173 shares of the company’s stock valued at $128,090,000 after purchasing an additional 219,659 shares during the last quarter. DAVENPORT & Co LLC boosted its stake in Enovis by 12.6% in the fourth quarter. DAVENPORT & Co LLC now owns 1,879,425 shares of the company’s stock worth $105,920,000 after purchasing an additional 210,358 shares in the last quarter. Finally, First Eagle Investment Management LLC boosted its stake in Enovis by 13,924.1% in the third quarter. First Eagle Investment Management LLC now owns 166,746 shares of the company’s stock worth $8,793,000 after purchasing an additional 165,557 shares in the last quarter. 98.45% of the stock is currently owned by institutional investors.

Enovis Stock Performance

ENOV stock opened at $52.62 on Thursday. Enovis Co. has a twelve month low of $43.04 and a twelve month high of $66.14. The company has a quick ratio of 1.03, a current ratio of 2.10 and a debt-to-equity ratio of 0.40. The company has a market cap of $2.89 billion, a P/E ratio of -35.08 and a beta of 1.99. The business’s fifty day moving average is $57.58 and its 200-day moving average is $56.10.

Enovis (NYSE:ENOVGet Free Report) last released its earnings results on Thursday, May 2nd. The company reported $0.50 earnings per share for the quarter, meeting the consensus estimate of $0.50. The firm had revenue of $516.00 million for the quarter, compared to analyst estimates of $505.62 million. Enovis had a positive return on equity of 3.98% and a negative net margin of 4.51%. The company’s quarterly revenue was up 27.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.44 earnings per share. Equities research analysts forecast that Enovis Co. will post 2.62 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Stephens initiated coverage on Enovis in a report on Tuesday, February 13th. They issued an “overweight” rating and a $72.00 price target for the company. Needham & Company LLC reissued a “buy” rating and set a $82.00 price target on shares of Enovis in a research note on Friday, May 3rd. UBS Group started coverage on shares of Enovis in a report on Monday, January 22nd. They issued a “buy” rating and a $75.00 price target for the company. Wells Fargo & Company upped their price objective on Enovis from $73.00 to $79.00 and gave the stock an “overweight” rating in a report on Friday, February 23rd. Finally, Canaccord Genuity Group lifted their target price on Enovis from $73.00 to $75.00 and gave the company a “buy” rating in a research note on Friday, February 23rd. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $75.43.

Get Our Latest Analysis on ENOV

Enovis Company Profile

(Free Report)

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.

Recommended Stories

Institutional Ownership by Quarter for Enovis (NYSE:ENOV)

Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.